Trending...
- Stop Bleeding Cash on Mediocre Talent. Build a Powerhouse Remote Team Instead
- Tickeron Highlights AI Trading Agent Performance Across Multiple Market Sectors
- New Book Calls 'Sense of Belonging' the Missing Link in Student Success
BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith reminds investors of the upcoming June 6, 2022 deadline to file a lead plaintiff motion in the case filed on behalf of investors who purchased AbbVie Inc. ("AbbVie" or the "Company") (NYSE: ABBV) securities between April 30, 2021 and August 31, 2021, inclusive (the "Class Period").
Investors suffering losses on their AbbVie investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
AbbVie's Janus kinase ("JAK") inhibitor drug, Rinvoq, has been approved by the U.S. Food and Drug Administration ("FDA") for the treatment of moderate to severe rheumatoid arthritis ("RA"). In 2020, AbbVie sought regulatory approval to expand the indications for Rinvoq.
On June 25, 2021, AbbVie disclosed that the FDA would not complete its review of several of the expanded treatment indications for Rinvoq within the previously-announced timeframe due to its ongoing evaluation of safety concerns associated with other JAK inhibitor drugs.
More on The PennZone
On this news, AbbVie's common stock fell $1.76, or 1.5%, to close at $112.98 per share on June 25, 2021, thereby injuring investors.
Then, on September 1, 2021, the FDA announced that the safety trials for another JAK inhibitor drug, Xeljanz, had established an increased risk of serious adverse events, even with low doses, and determined that new and updated warnings would be required for those drugs as well as for Rinvoq, as it shares "similar mechanisms of action" and "may have similar risks." The FDA also disclosed that it would further limit approved indications for Rinvoq as a result of safety concerns.
On this news, AbbVie's common stock fell $8.51, or 7%, to close at $112.27 per share on September 1, 2021, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
If you purchased or otherwise acquired AbbVie securities during the Class Period, you may move the Court no later than June 6, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
Investors suffering losses on their AbbVie investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to howardsmith@howardsmithlaw.com.
AbbVie's Janus kinase ("JAK") inhibitor drug, Rinvoq, has been approved by the U.S. Food and Drug Administration ("FDA") for the treatment of moderate to severe rheumatoid arthritis ("RA"). In 2020, AbbVie sought regulatory approval to expand the indications for Rinvoq.
On June 25, 2021, AbbVie disclosed that the FDA would not complete its review of several of the expanded treatment indications for Rinvoq within the previously-announced timeframe due to its ongoing evaluation of safety concerns associated with other JAK inhibitor drugs.
More on The PennZone
- Charmaine Thompson Turns Pain Into Purpose Through Woman of Power Charmcare
- Buy Retatrutide Research Peptide: Why Reta Is Getting So Much Attention
- San Diego Attorney Anthony Z. Vargas Narrows Practice to Employment Law, Representing Employees Only
- Solid Earth Introduces RealtyID, a Universal Identity Spine for the Real Estate Industry
- GGILabs Expands Local SEO Services to Help Businesses Compete in AI-Driven Search
On this news, AbbVie's common stock fell $1.76, or 1.5%, to close at $112.98 per share on June 25, 2021, thereby injuring investors.
Then, on September 1, 2021, the FDA announced that the safety trials for another JAK inhibitor drug, Xeljanz, had established an increased risk of serious adverse events, even with low doses, and determined that new and updated warnings would be required for those drugs as well as for Rinvoq, as it shares "similar mechanisms of action" and "may have similar risks." The FDA also disclosed that it would further limit approved indications for Rinvoq as a result of safety concerns.
On this news, AbbVie's common stock fell $8.51, or 7%, to close at $112.27 per share on September 1, 2021, thereby injuring investors further.
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors; (2) as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
More on The PennZone
- Sara Viteri, Turnstone Creative Senior Producer, Named to Lehigh Valley Business' Forty Under 40
- Boyertown Mechanic Travels to Nashville to Learn How AI Is Changing Auto Repair
- Colonial Nissan Earns Capital One Top Performing Dealership Award
- BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
- Logistics Expert Asks A Question Biology Has Overlooked: How Evolution Assembles Coordinated Novelty
If you purchased or otherwise acquired AbbVie securities during the Class Period, you may move the Court no later than June 6, 2022 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020, by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Contacts
Law Offices of Howard G. Smith
Howard G. Smith, Esquire
215-638-4847
888-638-4847
howardsmith@howardsmithlaw.com
www.howardsmithlaw.com
0 Comments
Latest on The PennZone
- New Research Finds a Good Deal Is All It Takes to Get Americans Booking a Last-Minute Vacation — and Most Already Have One on Their Mind
- GitKraken Introduces GitLens 19, Bringing Human and AI Workflows Together in One Workbench
- LĪNA Universal Balm Nominated for "Best Clean Skincare Product" at CertClean Beauty Awards
- Bronze Stevie Award Recognizes Satyadhar Joshi for AI Research and Public Policy Engagement
- synseer Nominated for Best Startup in 2026 Prix Galien USA Awards Following Record Breaking Applicant Pool
- Leading PDR Training Courses in Canada: Learn Paintless Dent Repair with PDR Academy & Tint Academy
- Move in this Fall! New Released Quick Move-In Townhomes at Heritage at South Brunswick with Limited-Time Incentives
- Rebecca L. Francis, Founder of the Rebecca Francis Team, Named to Lehigh Valley Business' LVB 300
- Crossroads4Hope Marks 25 Years Ensuring No One Faces Cancer Alone At its Inspiring Hope Gala
- Imagen Golf & Top 100 Coach Daniel Guest Voted Best Golf Instruction Firm of the Year 2026
- Q1 2026 Arizona Technology Industry Impact Report Recaps Advanced Manufacturing Growth, High-Value Jobs and Workforce Investment
- Former Prosecutor Opens Stegall Law in Summerville
- Vboost Celebrates 14 years of Automotive Viral Marketing
- M.C. Weeks, Inc. Marks 80 Years of Family Ownership and Brand Refresh
- Ignazio Arces Wins Stevie® Award for Maverick of the Year at the 2026 International Business Awards
- SMACK Fighting Championships Debuts a New Sports Concept in Philadelphia
- Tickeron Highlights AI Trading Agent Performance Across Multiple Market Sectors
- Stop Bleeding Cash on Mediocre Talent. Build a Powerhouse Remote Team Instead
- Crownlight Strategies® Announces Federal Trademark Registration
- New Book Calls 'Sense of Belonging' the Missing Link in Student Success